(Q33785190)

English

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus (English)

1 reference

Europe PubMed Central

29 July 2017

type-1 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

Tim Heise

1

1 reference

Europe PubMed Central

29 July 2017

Leszek Nosek

2

1 reference

Europe PubMed Central

29 July 2017

Carsten Roepstorff

3

1 reference

Europe PubMed Central

29 July 2017

Suresh Chenji

4

1 reference

Europe PubMed Central

29 July 2017

Oliver Klein

5

1 reference

Europe PubMed Central

29 July 2017

Hanne Haahr

6

1 reference

Europe PubMed Central

29 July 2017

publication date

3 June 2014

1 reference

Europe PubMed Central

29 July 2017

Diabetes Therapy

1 reference

Europe PubMed Central

29 July 2017

5

1 reference

Europe PubMed Central

29 July 2017

1

1 reference

Europe PubMed Central

29 July 2017

255-265

1 reference

Europe PubMed Central

29 July 2017

copyright license

Creative Commons Attribution 4.0 International

1 June 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s13300-014-0070-2

0 references

Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065302

4 July 2018

The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065302

4 July 2018

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065302

4 July 2018

Standards of medical care in diabetes--2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065302

4 July 2018

Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065302

4 July 2018

Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065302

4 July 2018

Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065302

4 July 2018

A review of types 1 and 2 diabetes mellitus and their treatment with insulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065302

4 July 2018

Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0070-2

21 January 2018

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0070-2

21 January 2018

The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0070-2

21 January 2018

Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0070-2

21 January 2018

Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0070-2

21 January 2018

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0070-2

21 January 2018

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0070-2

21 January 2018

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0070-2

21 January 2018

Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0070-2

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0070-2

21 January 2018

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24888255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Action profile of the rapid acting insulin analogue: human insulin B28Asp

1 reference

https://pubmed.ncbi.nlm.nih.gov/24888255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture

1 reference

https://pubmed.ncbi.nlm.nih.gov/24888255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/24888255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24888255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13300-014-0070-2

1 reference

Europe PubMed Central

29 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33785190&oldid=1861591043"